Simona Soverini

Simona Soverini

UNVERIFIED PROFILE

Are you Simona Soverini?   Register this Author

Register author
Simona Soverini

Simona Soverini

Publications by authors named "Simona Soverini"

Are you Simona Soverini?   Register this Author

100Publications

2878Reads

14Profile Views

Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis.

Hematol Oncol 2020 Jan 28. Epub 2020 Jan 28.

Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale-DIMES-Istituto di Ematologia "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2703DOI Listing
January 2020

Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update.

Int J Mol Sci 2019 Dec 5;20(24). Epub 2019 Dec 5.

Department of Experimental, Diagnostic and Specialty Medicine, Hematology/Oncology "L. e A. Seràgnoli", University of Bologna, 40138 Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20246141DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940932PMC
December 2019

Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type.

Leukemia 2019 10 27;33(10):2358-2364. Epub 2019 Aug 27.

Institute of Hematology "Lorenzo and Ariosto Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi University Hospital, University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0562-1DOI Listing
October 2019

Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the of Molecular Hematology.

Front Oncol 2019 23;9:863. Epub 2019 Sep 23.

Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology L. and A. Seràgnoli, S. Orsola-Malpighi University Hospital, University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00863DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768007PMC
September 2019

The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview.

Leukemia 2019 05 23;33(5):1173-1183. Epub 2019 Jan 23.

Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Ludwig-Maximilians-Universität München, Munich, Germany.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41375-018-0341-4
Publisher Site
http://dx.doi.org/10.1038/s41375-018-0341-4DOI Listing
May 2019

BCR-ABL1 mutation screening in chronic myeloid leukaemia: is next now?

Lancet Haematol 2019 May;6(5):e236-e237

Institute of Hematology "L. e A. Seràgnoli", Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, 40138 Bologna, Italy.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23523026193004
Publisher Site
http://dx.doi.org/10.1016/S2352-3026(19)30046-8DOI Listing
May 2019

Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges.

J Hematol Oncol 2019 04 23;12(1):39. Epub 2019 Apr 23.

Children's Cancer Research Institute (CCRI) and Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
https://jhoonline.biomedcentral.com/articles/10.1186/s13045-
Publisher Site
http://dx.doi.org/10.1186/s13045-019-0729-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6480772PMC
April 2019

Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis.

Pharmacol Res 2018 05 7;131:244-254. Epub 2018 Feb 7.

Department of Pharmaceutical Sciences and Interdepartmental Research Center of Pharmacogenetics and Pharmacogenomics (CRIFF), University of Piemonte Orientale, Novara, Italy. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10436618173152
Publisher Site
http://dx.doi.org/10.1016/j.phrs.2018.02.005DOI Listing
May 2018

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy.

Mol Cancer 2018 02 19;17(1):49. Epub 2018 Feb 19.

Hematology/Oncology "L. e A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12943-018-0780-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817796PMC
February 2018

What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer?

Hematol Oncol 2017 Dec 19;35(4):420-423. Epub 2016 Jul 19.

Laboratory of Mammary and Leukemic Oncogenesis: Genetic Diversity and Resistance to Treatment, ACTION, INSERM U1218, University of Bordeaux, Bordeaux, Gironde, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2329DOI Listing
December 2017

FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage.

J Cell Biochem 2017 11 30;118(11):3968-3975. Epub 2017 May 30.

Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Institute of Hematology L. and A. Seràgnoli-University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.26052DOI Listing
November 2017

Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemia.

Oncotarget 2017 Oct 22;8(50):88244-88250. Epub 2017 Sep 22.

Department of Experimental Diagnostic and Specialty Medicine, DIMES-Institute of Hematology "L. and A. Seràgnoli", University of Bologna Medical School, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.21166DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675707PMC
October 2017

The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.

BMC Cancer 2017 Aug 5;17(1):523. Epub 2017 Aug 5.

Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Via Massarenti, 9-40138, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-017-3511-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5545087PMC
August 2017

Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemia.

Lancet Haematol 2016 12;3(12):e554-e555

University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(16)30170-3DOI Listing
December 2016

Present and future of molecular monitoring in chronic myeloid leukaemia.

Br J Haematol 2016 05 7;173(3):337-49. Epub 2016 Mar 7.

Department of Experimental, Diagnostic and Specialty Medicine, Haematology/Oncology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13966DOI Listing
May 2016

Best Practices in Chronic Myeloid Leukemia Monitoring and Management.

Oncologist 2016 05 31;21(5):626-33. Epub 2016 Mar 31.

Department of Experimental, Diagnostic and Specialty Medicine, Hematology/Oncology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0337DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861357PMC
May 2016

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.

Blood 2016 Feb 24;127(6):703-12. Epub 2015 Nov 24.

Department of Genetics and Molecular Pathology, SA Pathology, Centre for Cancer Biology, School of Medicine and School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia; and School of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-08-660977DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760131PMC
February 2016

Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.

Am Soc Clin Oncol Educ Book 2014 :167-75

From the Department of Hematology-Oncology 'L. and A. Seràgnoli', and the Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2014.34.167DOI Listing
November 2015

Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.

Clin Lymphoma Myeloma Leuk 2015 Jun;15 Suppl:S120-8

Department of Experimental, Diagnostic and Specialty Medicine, Hematology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2015.02.035DOI Listing
June 2015

BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia.

PLoS One 2013 10;8(12):e81425. Epub 2013 Dec 10.

Istituto di Ematologia "Lorenzo e Ariosto Seràgnoli", Dipartimento di Medicina Specialistica Diagnostica e Sperimentale - DIMES, University of Bologna - Medical School, Bologna, Italy.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0081425PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858264PMC
March 2015

Interferon in CML: back to the past, or towards the future?

Lancet Haematol 2015 Jan 7;2(1):e8-9. Epub 2015 Jan 7.

Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Unit of Hematology, University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(14)00038-6DOI Listing
January 2015

Molecular monitoring.

Curr Hematol Malig Rep 2014 Mar;9(1):1-8

Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Via Massarenti 9, 40138, Bologna, Italy,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-013-0192-zDOI Listing
March 2014

Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis.

Pharmacogenomics 2012 Aug;13(11):1271-84

Department of Hematology/Oncology L. e A. Seragnoli, S. Orsola-Malpighi Hospital, Via Massarenti 9, 40138, University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs.12.103DOI Listing
August 2012

Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure.

Haematologica 2009 Dec 16;94(12):1758-61. Epub 2009 Jul 16.

Department of Hematology and Medical Oncology L. and A. Seràgnoli, St. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2009.010496DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2791949PMC
December 2009

Response definitions and European Leukemianet Management recommendations.

Best Pract Res Clin Haematol 2009 Sep;22(3):331-41

Department of Hematology-Oncology L. and A. Seràgnoli, S.Orsola-Malpighi University Hospital, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2009.10.001DOI Listing
September 2009

New targets for Ph+ leukaemia therapy.

Best Pract Res Clin Haematol 2009 Sep;22(3):445-54

Department of Hematology/Oncology L. and A. Seràgnoli S.Orsola Malpighi Hospital, University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2009.08.002DOI Listing
September 2009

New mechanisms of resistance in Philadelphia chromosome acute lymphoblastic leukemia.

Expert Rev Hematol 2009 Jun;2(3):297-303

Department of Hematology/Oncology L and A Seràgnoli, S. Orsola Malpighi Hospital, University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/ehm.09.16DOI Listing
June 2009

Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia.

Semin Hematol 2009 Apr;46(2 Suppl 3):S22-6

Department of Leukemia, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2009.01.009DOI Listing
April 2009

Intermittent targeting as a tool to minimize toxicity of tyrosine kinase inhibitor therapy.

Nat Clin Pract Oncol 2009 Feb 17;6(2):68-9. Epub 2008 Dec 17.

Department of Hematology and Oncological Sciences, L e A Seràgnoli S Orsola-Malpighi Hospital, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncponc1276DOI Listing
February 2009

Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation.

Mol Cancer Ther 2008 Sep;7(9):2692-702

Oncologia Molecolare, Istituto Nazionale per la Ricerca sul Cancro, L.go R.Benzi, 10, 16132 Genova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-08-0132DOI Listing
September 2008

Imatinib mesylate for the treatment of chronic myeloid leukemia.

Expert Rev Anticancer Ther 2008 Jun;8(6):853-64

Department of Hematology & Oncological Sciences "Lorenzo e Ariosto Seràgnoli" University of Bologna, Via Massarenti 9, 40138 Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.8.6.853DOI Listing
June 2008